search
Back to results

Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Amprenavir (drug)
ABT-378/r (drug)
Ritonavir (drug)
Sponsored by
French National Agency for Research on AIDS and Viral Hepatitis
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring HIV infections, Salvage therapy, Amprenavir, Lopinavir, Ritonavir

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Documented HIV infection CD4 cell count below 300/mm3 Plasma HIV RNA over 30,000 copies/ml Previously treated with 2 protease inhibitors and 1 non nucleoside analogue (except amprenavir, lopinavir) Written informed consent Exclusion Criteria: Biological abnormalities Pregnancy Alcool abuse History of pancreatitis, hepatic failure Acute HIV related infection Chemotherapy

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Mean change of VIH RNA between week 0 and week 26

    Secondary Outcome Measures

    Disease progression
    CD4 cell count
    Safety
    Pharmacokinetics
    Genotypic resistance

    Full Information

    First Posted
    September 12, 2005
    Last Updated
    September 12, 2005
    Sponsor
    French National Agency for Research on AIDS and Viral Hepatitis
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00196625
    Brief Title
    Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.
    Official Title
    Study on Safety and Efficacy of Salvage Therapy With Amprenavir, Lopinavir and Ritonavir 200 Mg/d or 400 Mg/d in HIV-Infected Patients in Virological Failure.ANRS 104 PUZZLE 1
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2005
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2000 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    February 2002 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    French National Agency for Research on AIDS and Viral Hepatitis

    4. Oversight

    5. Study Description

    Brief Summary
    HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.
    Detailed Description
    HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors (NRTI), over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed. 100 patients with CD4 cell count below 300/mm3 and plasma HIV RNA over 30,000 copies/ml are to be included in four groups: amprenavir, lopinavir, NRTI, with ritonavir 200 mg.d or not (patients previously treated by additional ritonavir 200 or 400 mg/d).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    HIV Infections
    Keywords
    HIV infections, Salvage therapy, Amprenavir, Lopinavir, Ritonavir

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    100 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Amprenavir (drug)
    Intervention Type
    Drug
    Intervention Name(s)
    ABT-378/r (drug)
    Intervention Type
    Drug
    Intervention Name(s)
    Ritonavir (drug)
    Primary Outcome Measure Information:
    Title
    Mean change of VIH RNA between week 0 and week 26
    Secondary Outcome Measure Information:
    Title
    Disease progression
    Title
    CD4 cell count
    Title
    Safety
    Title
    Pharmacokinetics
    Title
    Genotypic resistance

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Documented HIV infection CD4 cell count below 300/mm3 Plasma HIV RNA over 30,000 copies/ml Previously treated with 2 protease inhibitors and 1 non nucleoside analogue (except amprenavir, lopinavir) Written informed consent Exclusion Criteria: Biological abnormalities Pregnancy Alcool abuse History of pancreatitis, hepatic failure Acute HIV related infection Chemotherapy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gilles Raguin, MD
    Organizational Affiliation
    Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Genevieve Chene, MD, PhD
    Organizational Affiliation
    INSERM U593, Bordeaux, France
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    15456093
    Citation
    Raguin G, Chene G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM; Puzzle 1 Study Group. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther. 2004 Aug;9(4):615-25.
    Results Reference
    result
    PubMed Identifier
    15060509
    Citation
    Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chene G, Clavel F, Girard PM. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2004 Apr;75(4):310-23. doi: 10.1016/j.clpt.2003.12.013.
    Results Reference
    result

    Learn more about this trial

    Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.

    We'll reach out to this number within 24 hrs